LAS VEGAS, NV -- December 4, 2024
-- InvestorsHub NewsWire -- Avant Technologies Inc.’s (OTCQB:
AVAI) (“Avant” or the “Company”), partner, Ainnova Tech, Inc.,
(Ainnova) a leading healthcare technology company focused on
revolutionizing early disease detection using artificial
intelligence (AI), today announced that the company has entered
into a strategic alliance with global biotech, Roche, and leading
pre-paid health plan provider, Salud 360, to begin a pilot program
to combat diabetic retinopathy using Ainnova’s cutting-edge
technology.
The pilot program will initially be
implemented in Costa Rica where diabetes affects about 10.4% of the
adult population.[1] If successful, Avant and
Ainnova hope to implement a similar program in the United States,
Canada, and Europe through Ai-nova Acquisition Corp. (AAC), the
company formed by the partnership between Avant and
Ainnova.
According to data from the Costa
Rican Institute for Research and Teaching in Nutrition and Health
(Inciensa), uncontrolled diabetes is the leading cause of
preventable blindness in the country's adult population. To make
matters worse, between 20% and 40% of diabetic patients develop
diabetic retinopathy, a silent but devastating condition if not
detected and treated in time.
According to the World Health
Organization, 80% of cases of blindness due to diabetes are
preventable with early and effective
interventions.[2] Therefore, early detection is
crucial and technological innovation can help make a huge
difference.
Roche, Ainnova, and Salud 360
signed a strategic alliance to improve access to vision screening
in patients with uncontrolled diabetes with the hope of decreasing
the risks of diabetic retinopathy using Ainnova’s advanced
technology and a patient-centered approach.
The pilot program will use
non-mydriatic fundus cameras and artificial intelligence -
developed by Ainnova Tech - to automatically analyze retinal images
and identify microscopic changes in the retina. Such changes would
be an early indicator of diabetic retinopathy without the need for
invasive tests.
“At Roche, we are committed to
timely diagnosis of diseases to improve clinical outcomes and thus
contribute to the sustainability of the healthcare system. By
leveraging technology, we seek to improve lives, optimize
diagnoses, and ensure that every patient has access to timely and
effective treatment. With this model, we not only seek to address
the problem of diabetic retinopathy, but also to establish a
replicable path for other diseases that require innovative
solutions,” said, Alvaro Soto, General Manager of Roche Central
America, Caribbean, and Venezuela.
By implementing the pilot program
in Costa Rica, this strategic alliance can take advantage of the
country's robust healthcare system and its focus on technological
innovation. Patients who are members of Salud 360 will be the first
to benefit from screenings at affiliated clinics. Those at risk
will be referred immediately to ophthalmology specialists,
guaranteeing comprehensive and timely care.
The results of this pilot program
will be the basis for developing the model beyond our borders to
benefit communities facing similar challenges in accessing medical
care.
Vinicio Vargas, Chief Executive
Officer of Ainnova Tech and member of AAC’s Board of Directors,
emphasized, “We are proud to be able to put our technology at the
service of a project that has the potential to prove itself as a
massive impact model in early detection, and which we believe is
replicable globally. Today, we are starting with diabetic
retinopathy, but the vision is that we can eventually multiply this
same effort for other critical diseases that require innovative
solutions.”
About Ainnova Tech, Inc.
Ainnova is a Nevada-based
healthtech startup with headquarters in San Jose, Costa Rica, and
Houston, Texas. Founded by an experienced and innovative team that
is dedicated to leveraging artificial intelligence for early
disease detection. Recognized with multiple global awards and
renowned partnerships with hospitals and medical device companies,
we proudly introduce VisionAI – our cutting-edge platform designed
to prevent blindness and detect the early onset of diabetes.
Explore how Ainnova is revolutionizing healthcare through advanced
technology and proactive solutions.
About Avant Technologies, Inc.
Avant Technologies Inc. is an
emerging technology company developing solutions in artificial
intelligence in healthcare. With a focus on pushing the boundaries
of what is possible in AI and machine learning, Avant serves a
diverse range of industries, driving progress and efficiency
through state-of-the-art technology.
More information about Avant can be
found at https://avanttechnologies.com
You can also follow us on social
media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in
this press release may constitute “forward-looking
statements.” Forward-looking statements provide current
expectations of future events based on certain assumptions and
include any statement that does not directly relate to any
historical or current fact. Actual results may differ
materially from those indicated by such forward-looking statements
because of various important factors as disclosed in our filings
with the Securities and Exchange Commission located at their
website (http://www.sec.gov). In
addition to these factors, actual future performance, outcomes, and
results may differ materially because of more general factors
including (without limitation) general industry and market
conditions and growth rates, economic conditions, governmental and
public policy changes, the Company’s ability to raise capital on
acceptable terms, if at all, the Company’s successful development
of its products and the integration into its existing products and
the commercial acceptance of the Company’s products. The
forward-looking statements included in this press release represent
the Company's views as of the date of this press release and these
views could change. However, while the Company may elect
to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do
so. These forward-looking statements should not be
relied upon as representing the Company's views as of any date
after the date of the press release.
Contact:
Avant Technologies Inc.
info@avanttechnologies.com
Avant Technologies (QB) (USOTC:AVAI)
過去 株価チャート
から 11 2024 まで 12 2024
Avant Technologies (QB) (USOTC:AVAI)
過去 株価チャート
から 12 2023 まで 12 2024
